Home › Research › Risk genes beyond APOE
Impact of Cytokines and Chemokines on Alzheimer's Disease Neuropathological Hallmarks
Domingues C, da Cruz E Silva OAB, Henriques AG.. Current Alzheimer research, 2017-01-01
Topic: Amyloid, tau and blood-test diagnosis
Background Alzheimer's disease (AD) is the most common neurodegenerative disorder, neuropathologically characterized by aggregates of β-amyloid peptides, which deposit as senile plaques, and of TAU protein, which forms neurofibrillary tangles. It is now widely accepted that neuroinflammation is implicated in AD pathogenesis. Method Indeed, inflammatory mediators, such as cytokines and chemokines (chemotactic cytokines) can impact on the Alzheimer´s amyloid precursor protein by affecting its expression levels and amyloidogenic processing and/or β -amyloid aggregation.
Key findings
- It is now widely accepted that neuroinflammation is implicated in AD pathogenesis.
- Method Indeed, inflammatory mediators, such as cytokines and chemokines (chemotactic cytokines) can impact on the Alzheimer´s amyloid precursor protein by affecting its expression levels and amyloidogenic processing and/or β -amyloid aggregation.
- Additionally, cytokines and chemokines can influence kinases' activities, leading to abnormal TAU phosphorylation.
- To date there is no cure for AD, but several therapeutic strategies have been directed to prevent neuroinflammation.
Why it matters
This review states that neuroinflammation is implicated in Alzheimer's disease and that cytokines and chemokines can affect amyloid precursor protein expression and processing and can influence kinases that phosphorylate TAU. It notes there is still no cure for the disease, and it describes possible therapeutic approaches rather than a proven treatment.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 44/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Current Alzheimer research) |
| Journal's citation record | 1 / 4 | Current Alzheimer Research: journal h-index 119 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2017 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 214 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 19.5 citations a year over 11 year(s) since 2017 |
| Impact for its field and year | 4 / 6 | Cited 9.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 6 other studies in this library |
| Still being cited | 3 / 4 | Cited 75 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Ana Gabriela Henriques: h-index 21 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | University of Aveiro: institution h-index 462 (OpenAlex) |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 28317487) |
| Free to read | 2 / 2 | Free to read |
| Total | 44 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.2174/1567205014666170317113606
- PubMed: 28317487
- Original source →
- Free full text: Current Alzheimer Research →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Domingues, C., da Cruz E Silva, O. A. B., & Henriques, A. G. (2017). Impact of Cytokines and Chemokines on Alzheimer's Disease Neuropathological Hallmarks. Current Alzheimer research. https://doi.org/10.2174/1567205014666170317113606
Vancouver
Domingues C, da Cruz E Silva OAB, Henriques AG. Impact of Cytokines and Chemokines on Alzheimer's Disease Neuropathological Hallmarks. Current Alzheimer research. 2017. doi:10.2174/1567205014666170317113606. PMID: 28317487.
BibTeX
@article{domingues2017-28317487,
author = {Domingues, C. and da Cruz E Silva, O. A. B. and Henriques, A. G.},
title = {{Impact of Cytokines and Chemokines on Alzheimer's Disease Neuropathological Hallmarks}},
journal = {Current Alzheimer research},
year = {2017},
doi = {10.2174/1567205014666170317113606},
pmid = {28317487},
url = {https://doi.org/10.2174/1567205014666170317113606}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 28.
Later studies that cite this one
6 studies in the alzhub library list this one in their references.